Synapse - Works

Results (4640)

nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT)

Meeting Abstract

Tempero, M. A.; Cardin, D. B.; Biankin, A.; Goldstein, D.; Moore, M.; O'Reilly, E. M.; Philip, P. A.; Riess, H.; Macarulla, T.; Yung, L.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Recent and remote 30-day readmissions among cancer patients: Prevalence and association with overall survival

Meeting Abstract

Shahrokni, A.; Temple, L. K. F.; Mahmoudzadeh, S.; Wills, J.; Sepkowitz, K.; Martin, S.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Integration of multi-modality treatment planning for early stage breast cancer (BC) into Watson for Oncology, a Decision Support System: Seeing the forest and the trees

Meeting Abstract

Seidman, A. D.; Pilewskie, M. L.; Robson, M. E.; Kelvin, J. F.; Zauderer, M. G.; Epstein, A. S.; Kris, M. G.; Fu, J.; Keesing, J.; Caroline, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Meeting Abstract

Segal, N. H.; Ou, S. H. I.; Balmanoukian, A. S.; Fury, M. G.; Massarelli, E.; Brahmer, J. R.; Weiss, J.; Schöffski, P.; Antonia, S. J.; Massard, C.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)

Meeting Abstract

Rizvi, N. A.; Brahmer, J. R.; Ou, S. H. I.; Segal, N. H.; Khleif, S.; Hwu, W. J.; Gutierrez, M.; Schöffski, P.; Hamid, O.; Weiss, J.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Treatment response and outcomes of grade 3 (G3) pancreatic neuroendocrine carcinomas (HGNEC) based on pathologic differentiation

Meeting Abstract

Raj, N. P.; Valentino, E.; Tang, L. H.; Capanu, M.; Basturk, O.; Klimstra, D.; Reidy, D. L.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Prospective molecular analysis of small cell lung cancer (SCLC) using next generation sequencing (NGS)

Meeting Abstract

Pietanza, M. C.; Won, H. H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Krug, L. M.; Varghese, A. M.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy

Meeting Abstract

O'Reilly, E. M.; Walker, C.; Clark, J.; Brill, K. J.; Dawkins, F. W.; Bendell, J. C.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results

Meeting Abstract

O'Reilly, E. M.; Mahalingam, D.; Roach, J. M.; Schultes, B. C.; Rosano, M. E.; Miller, P. J.; Wolf, J.; Flaherty, K.; Ryan, D. P.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer

Meeting Abstract

Moore, K. N.; Varghese, A. M.; Hyman, D. M.; Callies, S.; Lin, J.; Wacheck, V.; Pant, S.; Bauer, T. M.; Bendell, J. C.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save